NCT06117891 - An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

November 27, 2026

Study Completion Date

February 1, 2027

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

DRUG

Atezolizumab

Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.

DRUG

Bevacizumab

Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.

DRUG

Durvalumab

Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.

DRUG

Tremelimumab,

Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.

Trial Locations (20)

NOT_YET_RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

NOT_YET_RECRUITING

Corporal Michael J Crescenz Department Of Veterans Affairs Medical Center, Philadelphia

NOT_YET_RECRUITING

Einstein Medical Center, Philadelphia

NOT_YET_RECRUITING

Mercy Medical Center - Medline Healthcare Services LLC, Baltimore

NOT_YET_RECRUITING

University Of Cincinnati Division Of Hematology Oncology - UC Health System, Cincinnati

NOT_YET_RECRUITING

University of Michigan Health System, Ann Arbor